Rising preeclampsia cases globally drives growth of preeclampsia diagnostics market from USD 2.32 Bn in 2025
Get a
Sample Report of Preeclampsia Diagnostics Market
@ https://www.coherentmarketinsights.com/insight/request-sample/4606
Key Takeaways of the Global Preeclampsia Diagnostics Market
• Treatment Types: Topical
treatments are anticipated to hold the largest market share, estimated at 670.88
million in 2025, due to their non-invasive nature and minimal side effects. • End Users: Hospitals are
expected to be the primary end-users, accounting for USD 705.28 million of the
market share in 2025, followed by dermatology clinics and homecare settings.
• Regional Distribution:
North America is projected to lead the market with a USD 914.88 million share
in 2024, attributed to high disease prevalence and advanced healthcare
infrastructure. Rising Preeclampsia Cases and Increased Awareness Drive Growth A new report by Coherent Market Insights outlines significant
trends in preeclampsia diagnostics market. Rising
preeclampsia cases globally and increasing awareness and screening for
preeclampsia fuels growth of preeclampsia
diagnostics market. Challenges in the Preeclampsia Diagnostics
Market: Awareness, Accessibility, and Early Detection Barriers The market for preeclampsia diagnostics has a number of
challenges, among them low awareness in low-resource settings, thus resulting
in late diagnosis. Additionally, high expenses of sophisticated diagnostic
equipment also make them unavailable for underserved populations. The intricacy
of the diagnosis, whereby preeclampsia overlaps with other conditions related
to pregnancy, and insufficient standardized testing regimens result in variable
outcomes. Inadequate screening programs for some areas and long regulatory approvals
for new tests also slow early detection. Buy
an Enterprise-User PDF of Preeclampsia Diagnostic Market Analysis & Outlook
2025-2032@ https://www.coherentmarketinsights.com/insight/buy-now/4606 Market Growth Opportunities The
preeclampsia diagnostic market presents a number of growth opportunities,
inspired by technological breakthroughs in diagnostics, including the creation
of more cost-effective, non-invasive, and precise technologies for the early
detection of the condition. Greater awareness and education concerning the
condition, especially in less developed areas, provide the opportunity to
increase screening programs and enhance maternal health outcomes. Government
programs and spending dedicated to the enhancement of maternal health also
present investment opportunities for diagnostic solutions. Also, personalized
medicine using biomarker and genetic profiling could open the door for more
accurate identification. With advancement of healthcare facilities in emerging
nations, there's increased demand for inexpensive diagnostic procedures.
Emerging Market Trend Government Programs and Funding: Most emerging market
governments are placing a focus on maternal health and investing in screening
programs and diagnostic technologies. This funding is driving the use of
preeclampsia diagnostics and the rates of early detection. Mobile Health and Point-of-Care Solutions: The
increasing use of mobile health technologies and point-of-care diagnostics in
developing markets is increasing the availability of preeclampsia screening,
particularly in rural and underserved communities. These affordable solutions
are transforming maternal health care by facilitating timely diagnosis and
control.
Analyst View:
The market for preeclampsia
diagnostics is set to experience tremendous growth as awareness regarding
maternal health improves and the incidence of preeclampsia, especially in
at-risk pregnancies, is on the rise. With improving healthcare infrastructure
all over the world, including emerging economies, the demand for sophisticated
diagnostic equipment is bound to increase. Mobile health and point-of-care
diagnostics are areas with major potential to increase access to preeclampsia
screenings in remote areas. Strategic partnerships among healthcare providers,
diagnostic firms, and government agencies will be critical to break these
barriers and facilitate timely detection and improved maternal health outcomes,
senior analyst Abhijeet Kale says.
Competitor Insights Key companies in the global
preeclampsia diagnostics market Key
Developments
• In June 2019, two blood
test products, the Elecsys sFlt-1 and PlGF immunoassays by F. Hoffmann-La Roche
Ltd., were approved by NHS England under the 'Innovation and Technology
Payment' program.
• In February 2019, Diabetomics,
Inc. released Lumella, the first point-of-care rapid test for preeclampsia
diagnosis in India. Lumella accurately quantifies the protein biomarker,
Glycosylated Fibronectin (GlyFN), in pregnant women with preeclampsia.
• In October 2018,
PerkinElmer Inc. formed a partnership with the Fetal Medicine Foundation (FMF),
a non-profit charity dedicated to improving the health of women and newborns.
Get Customization on this Report for
Specific Research Solutions@ https://www.coherentmarketinsights.com/insight/request-customization/4606
Detailed
Segmentation- By
Test Type
By
Product Type
By
End User By
Regional: Related Reports:
The Global Exosomes Diagnostic and Therapeutic
Market
is estimated to be valued at USD 92.8 Mn in 2025 and is
expected to reach USD 308.4 Mn by 2032, exhibiting a compound
annual growth rate (CAGR) of 18.7% from 2025 to 2032.
The Global diagnostic imaging services market is estimated to be valued
at USD 565.55 Bn in 2025 and is expected to reach USD 845.34 Bn
by 2032, exhibiting a compound annual growth rate (CAGR)
of 5.9% from 2025 to 2032.
The Global Diagnostic Radioisotopes Market is estimated to be valued
at USD 6.74 Bn in 2025 and is expected to reach USD 12.32 Bn in 2032,
exhibiting a compound annual growth rate (CAGR) of 9% from
2025 to 2032.
The Global Physician Office Diagnostic Market is estimated to be valued
at USD 135.3 Bn in 2025 and is expected to reach USD 334.42 Bn in 2032,
exhibiting a compound annual growth rate (CAGR) of 13.8% from
2025 to 2032.
The Global Pcos Diagnostic Market is estimated to be valued
at USD 3.9 Bn in 2025 and is expected to reach USD 5.49 Bn in 2032, exhibiting
a compound annual growth rate (CAGR) of 5% from 2025 to 2032.
About Us: Contact Us: Mr. Shah Phone:
US: + 12524771362 
Coherent
Market Insights leads into data and analytics, audience measurement, consumer
behaviors, and market trend analysis. From shorter dispatch to in-depth
insights, CMI has exceled in offering research, analytics, and consumer-focused
shifts for nearly a decade. With cutting-edge syndicated tools and custom-made
research services, we empower businesses to move in the direction of growth. We
are multifunctional in our work scope and have 450+ seasoned consultants,
analysts, and researchers across 26+ industries spread out in 32+ countries.
Senior Client Partner – Business Development
Coherent Market Insights
UK: +442039578553
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter